文献速递核素与放射性配体治疗

177Lu-Lu-DOTATATE治疗神经内分泌肿瘤的肿瘤吸收剂量与疗效关系

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.
PubMed 文献 · J Nucl Med · 2024-07-01

该回顾性研究基于临床试验中32例神经内分泌肿瘤患者的69个肿瘤,每个周期行177Lu-Lu-DOTATATE剂量学评估,共366次吸收剂量评估和712次肿瘤体积评估。混合效应模型和逻辑回归显示,2级神经内分泌肿瘤中累积肿瘤吸收剂量与体积缩小存在明确关系,累积剂量至少135 Gy时部分缓解概率约90%。

要点

  • 2级神经内分泌肿瘤中,肿瘤吸收剂量与体积缩小呈明确关系。
  • 累积肿瘤吸收剂量至少135 Gy时,部分肿瘤缓解概率约90%。
  • 研究基于32例患者69个肿瘤的366次剂量学评估和712次体积评估。

核心结论

  • 研究结果与既往关于肿瘤缩小与吸收剂量关系的观察一致,数据提示2级神经内分泌肿瘤部分缓解存在吸收剂量阈值,为剂量学指导的肽受体放射性核素治疗方案设计提供参考。

研究设计与样本

  • 回顾性研究,基于一项临床试验中32例接受177Lu-Lu-DOTATATE治疗的神经内分泌肿瘤患者的69个肿瘤。
  • 每个治疗周期行剂量学评估,共366次个体吸收剂量评估,采用平面-SPECT/CT混合显像、定量SPECT重建、基于体素的吸收剂量率计算、半自动图像分割和部分容积校正。
  • 在连续CT扫描上手动勾画每个肿瘤体积,共712次个体肿瘤体积评估,肿瘤按分级分层,采用混合效应模型和逻辑回归分析吸收剂量与疗效的关系,小于4 cm3的肿瘤被排除。

主要发现

  • 在2级神经内分泌肿瘤中,观察到吸收剂量与体积缩小之间存在明确关系。
  • 观察结果提示,累积肿瘤吸收剂量至少135 Gy时,部分肿瘤缓解概率约为90%。

关键数值与推荐

  • 2级神经内分泌肿瘤中,累积肿瘤吸收剂量至少135 Gy对应部分肿瘤缓解概率约90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and tumor response in a cohort of patients with NETs treated with [177Lu]Lu-DOTATATE. Methods: This was a retrospective study based on 69 tumors in 32 patients treated within a clinical trial. Dosimetry was performed at each cycle of [177Lu]Lu-DOTATATE, rendering 366 individual absorbed dose assessments. Hybrid planar-SPECT/CT imaging using [177Lu]Lu-DOTATATE was used, including quantitative SPECT reconstruction, voxel-based absorbed dose rate calculation, semiautomatic image segmentation, and partial-volume correction. Changes in tumor volume were used to determine tumor response. The volume for each tumor was manually delineated on consecutive CT scans, giving a total of 712 individual tumor volume assessments. Tumors were stratified according to grade. The relationship between absorbed dose and response was investigated using mixed-effects models and logistic regression. Tumors smaller than 4 cm3 were excluded. Results: In grade 2 NETs, a clear relationship between absorbed dose and volume reduction was observed. Our observations suggest a 90% probability of partial tumor response for an accumulated tumor-absorbed dose of at least 135 Gy. Conclusion: Our findings are in accordance with previous observations regarding the relationship between tumor shrinkage and absorbed dose. Moreover, our data suggest an absorbed dose threshold for partial response in grade 2 NETs. These observations provide valuable insights for the design of dosimetry-guided peptide receptor radionuclide therapy schemes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Warfvinge CF, Gustafsson J, Roth D, et al. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE. J Nucl Med. 2024. PMID: 38724277. doi:10.2967/jnumed.123.266991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。